In addition, LRRK2 antisense oligonucleotide treatment reduced pathologic aSyn inclusions, DA cell loss and associated motor deficits in PFF-treated WT mice, highlighting a role for endogenous, non-mutant LRRK2 in induced synucleinopathy [74]. The gene discussed is LRRK2; the disease is synucleinopathy.